Ascentage Pharma Group International (6855) Stock Overview
A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
6855 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Ascentage Pharma Group International Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$74.15 |
| 52 Week High | HK$86.70 |
| 52 Week Low | HK$26.05 |
| Beta | 0.83 |
| 1 Month Change | -6.55% |
| 3 Month Change | 43.98% |
| 1 Year Change | 174.63% |
| 3 Year Change | 362.86% |
| 5 Year Change | 133.54% |
| Change since IPO | 97.21% |
Recent News & Updates
Recent updates
Ascentage Pharma Group International's (HKG:6855) 25% Price Boost Is Out Of Tune With Revenues
Jun 10
Here's Why Shareholders Will Not Be Complaining About Ascentage Pharma Group International's (HKG:6855) CEO Pay Packet
May 12Ascentage Pharma Group International's (HKG:6855) 38% Price Boost Is Out Of Tune With Revenues
Apr 24
Takeda Deal And Olverembatinib Trials Will Open Global Markets
Ascentage's strategic alliances and NRDL inclusion are set to enhance market reach, boost accessibility, and drive substantial revenue growth.What Ascentage Pharma Group International's (HKG:6855) P/S Is Not Telling You
Dec 23Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up
Sep 04Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt
Aug 26Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up
Jun 18Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year
May 03Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge
Mar 30Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?
Feb 17There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price
Dec 20Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt
Oct 28Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates
Aug 27There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price
Aug 23Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt
Jun 19Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?
Dec 04Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?
Aug 30Shareholder Returns
| 6855 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -7.2% | -0.3% | 2.5% |
| 1Y | 174.6% | 166.8% | 43.1% |
Return vs Industry: 6855 exceeded the Hong Kong Biotechs industry which returned 166.8% over the past year.
Return vs Market: 6855 exceeded the Hong Kong Market which returned 43% over the past year.
Price Volatility
| 6855 volatility | |
|---|---|
| 6855 Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in HK Market | 15.3% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 6855 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6855's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 567 | Dajun Yang | www.ascentage.cn |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma.
Ascentage Pharma Group International Fundamentals Summary
| 6855 fundamental statistics | |
|---|---|
| Market cap | HK$27.57b |
| Earnings (TTM) | -HK$443.98m |
| Revenue (TTM) | HK$1.07b |
Is 6855 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6855 income statement (TTM) | |
|---|---|
| Revenue | CN¥980.65m |
| Cost of Revenue | CN¥29.09m |
| Gross Profit | CN¥951.57m |
| Other Expenses | CN¥1.36b |
| Earnings | -CN¥405.43m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 97.03% |
| Net Profit Margin | -41.34% |
| Debt/Equity Ratio | 597.6% |
How did 6855 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/26 17:56 |
| End of Day Share Price | 2025/07/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascentage Pharma Group International is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yang Huang | BofA Global Research |
| Jin Zhang | China International Capital Corporation Limited |
| Wangbin Zhou | China International Capital Corporation Limited |